Strongbridge Biopharma plc
SBBP · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $10 | $8 | $8 | $8 |
| % Growth | 19.8% | 1.9% | 1.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $10 | $8 | $8 | $8 |
| % Margin | 95.3% | 95.1% | 94.6% | 94.9% |
| R&D Expenses | $5 | $6 | $5 | $7 |
| G&A Expenses | $16 | $11 | $12 | $9 |
| SG&A Expenses | $16 | $11 | $13 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $1 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $23 | $18 | $18 | $17 |
| Operating Income | -$13 | -$10 | -$10 | -$10 |
| % Margin | -130.1% | -120.1% | -126.4% | -118.7% |
| Other Income/Exp. Net | -$0 | -$2 | -$2 | $6 |
| Pre-Tax Income | -$13 | -$12 | -$12 | -$3 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$13 | -$12 | -$12 | -$3 |
| % Margin | -131.9% | -140.9% | -145.2% | -39.1% |
| EPS | -0.2 | -0.18 | -0.21 | -0.056 |
| % Growth | -11.1% | 14.3% | -273% | – |
| EPS Diluted | -0.19 | -0.18 | -0.21 | -0.055 |
| Weighted Avg Shares Out | 68 | 67 | 56 | 56 |
| Weighted Avg Shares Out Dil | 68 | 67 | 56 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$11 | -$10 | -$10 | -$1 |
| % Margin | -111.1% | -116.4% | -123.1% | -16.9% |